Longitude Capital

Type

Venture Capital

Status

Active

Location

Menlo Park, United States

Total investments

124

Average round size

57M

Portfolio companies

79

Rounds per year

6.89

Lead investments

32

Follow on index

0.36

Exits

28

Stages of investment
Private EquityEarly Stage VentureLate Stage Venture
Areas of investment
BiotechnologyHealth CareHealth DiagnosticsManufacturingMedical DeviceMedicalLife SciencePharmaceuticalTherapeuticsBiopharma

Summary

Longitude Capital appeared to be the VC, which was created in 2006. The fund was located in North America if to be more exact in United States. The leading representative office of defined VC is situated in the Menlo Park.

Among the most successful fund investment fields, there are Health Diagnostics, Therapeutics. Besides, a startup requires to be at the age of 6-10 years to receive the investment from the fund. Among the most popular portfolio startups of the fund, we may highlight Alphaeon, CardioDx, SutroVax. The fund has exact preference in a number of founders of portfolio startups. When startup sums 5+ of the founder, the probability for it to get the investment is little. For fund there is a match between the location of its establishment and the land of its numerous investments - United States.

The standard case for the fund is to invest in rounds with 5-6 partakers. Despite the Longitude Capital, startups are often financed by Kleiner Perkins, The Carlyle Group, TVM Capital. The meaningful sponsors for the fund in investment in the same round are RA Capital Management, OrbiMed, Kleiner Perkins. In the next rounds fund is usually obtained by RA Capital Management, Rock Springs Capital, Kleiner Perkins.

The current fund was established by Marc Galletti, Patrick Enright. We also calculated 7 valuable employees in our database.

The common things for fund are deals in the range of 10 - 50 millions dollars. Opposing the other organizations, this Longitude Capital works on 1 percentage points less the average amount of lead investments. The real fund results show that this VC is 23 percentage points more often commits exit comparing to other companies. The increased amount of exits for fund were in 2018. When the investment is from Longitude Capital the average startup value is 500 millions - 1 billion dollars. The high activity for fund was in 2015. Despite it in 2019 the fund had an activity. The fund is constantly included in 2-6 deals per year.

Show more

Investor highlights

Industry focus
Biotech/Life SciencesHealthcare

Discover reliable insights

Find relevant VC investors, identify key contacts and secure funding opportunities.

Investments analytics

Last fund

Fund size
USD 585000000
Fund raised date
2020-09-01

Analytics

Total investments
124
Lead investments
32
Exits
28
Rounds per year
6.89
Follow on index
0.36
Investments by industry
  • Health Care (83)
  • Biotechnology (81)
  • Medical (40)
  • Therapeutics (33)
  • Pharmaceutical (32)
  • Show 31 more
Investments by region
  • United States (113)
  • Ireland (2)
  • Canada (4)
  • France (1)
  • Switzerland (1)
  • Show 1 more
Peak activity year
2021
Number of Unicorns
2
Number of Decacorns
2
Number of Minotaurs
1

Discover reliable insights

Leverage validated data, identify key contacts and secure funding opportunities for your business.

Quantitative data

Avg. startup age at the time of investment
11
Avg. valuation at time of investment
89M
Group Appearance index
0.93
Avg. company exit year
7
Avg. multiplicator
1.32
Strategy success index
0.90

Need more data?

Get access to full data about investors, including their team, contact information, and historic data.

Latest deals

Company name Deal date Industry Deal stage Deal size Location
Rivus Pharmaceuticals 22 Sep 2022 Biotechnology, Health Care, Medical, Pharmaceutical Early Stage Venture 132M United States, Virginia, Charlottesville
Zenas BioPharma 07 May 2024 Health Care, Pharmaceutical, Biopharma Late Stage Venture 200M

Similar funds

By same location

By same geo focus

By doing lead investments

How we get our data

At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).

Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.